Good pick on some of those controls DDD. Phosphagenics as the control arm might make it quite easy to show a significant benefit in the treatment group. In some of those companies the only "calming effect" would be a substantial increase in share price and I'm really not sure of any pharmaceuticals that have that effect. As always, GLTA
Ann: Commencement of BNC210 Phase 2 Agitation Trial, page-11
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
